ROXITHROMYCIN (ESPAROXY®) IN THE TREATMENT OF PATIENTS WITH PYODERMAS


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

He most common dermatoses among the population include pyodermas, which represent a large group of skin infectious diseases, developing as a result of the introduction of bacteria - pathogenic pyococcuses - into skin. Among the predominant pathogens of pyoderma, staphylococcuses causing staphylodermas and streptococcuses causing streptodermas, such as erysipelas, are predominant. Association of staphylococcuses and streptococcuses is a cause of streptostaphylodermas. In severe pyodermas, systemic antibiotic therapy is indicated. An effective drug of systemic antibiotic therapy in patients with pyodermas is roxithromycin (Esparoxy®). The data on the pharmacokinetics of roxithromycin, its efficacy and safety in the treatment of pyodermas, including erysipelas, are presented.

Full Text

Restricted Access

About the authors

V. V Chikin

FSBI State Research Center for Dermatology and Cosmetology of RMPH

Email: chikin@cnikvi.ru
PhD, Senior Scientist at the Department of Dermatology Moscow

References

  1. Самцов А.В., Теличко И.Н., Стаценко А.В., Хайрутдинов В.Р. Применение, наружных средств, содержащих соединения серебра, в терапии больных пиодермиями. Вестн. дерматологии и венерологии. 2014;1:75-80.
  2. Mahe A, Faye O., N'Diaye H.T., Ly F, Konare H., Кеita S., Traore A.K., Hay R. Definition of an algorithm for the management of common skin diseases at primary health care level in sub-Saharan Africa. Trans. R. Soc. Trop. Med. Hyg. 2005;99(1):39-47.
  3. Ki V., Rotstein C. Bacterial skin and soft tissue infections in adults: a review of their epidemiology, pathogenesis, diagnosis, treatment and site of care. Can. J. Infect. Dis. Med. Microbiol. 2008;192):173-84.
  4. Самцов А.В., Стаценко А.В., Хайрутдинов В.Р., Чаплыгин А.В. Сравнительное исследование клинической эффективности 3% тетрациклиновой мази и 2% мази мупироцина в терапии пиодермий. Вестн. дерматологии и венерологии. 2012;3:86-90.
  5. Ellis Simonsen S.M., van Orman E.R., Hatch B.E., Jones S.S., Gren L.H., Hegmann K.T., Lyon J.L. Cellulitis incidence in a defined population. Epidemiol. Infect. 2006;134:293-99.
  6. Eron L.J., Lipsky B.A., Low D.E., Nathwani D., Tice A,D, Volturo G,A.; Expert panel on managing skin and soft tissue infections. Managing skin and soft tissue infections: expert panel recommendations on key decision points. J. Antimicrob. Chemother. 2003; 52(Suppl.):3-17.
  7. Swartz M.N. Clinical practice. Cellulitis. N. Engl. J. Med. 2004;350:904-12.
  8. Brook I., Frazier E.H., Yeager J.K. Microbiology of nonbullous impetigo. Pediatr. Dermatol. 1997;14 (3):192-95.
  9. Moet G.J., Jones R.N., Biedenbach D.J., Stilwell M.G., Fritsche T.R. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Diagn. Microbiol. Infect. Dis. 2007;57(1):7-13.
  10. Stevens D.L., Bisno A.L., Chambers H.F., Everett E.D., Dellinger P., Goldstein E.J., Gorbach S.L., Hirschmann J.V., Kaplan E.L., Montoya J.G., Wade J.C. Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin. Infect. Dis. 2005;41(10):1373-406.
  11. Horowitz Y., Sperber A.D., Almog Y. Gramnegative cellulitis complicating cirrhosis. Mayo Clin. Proc. 2004;79:247-50.
  12. Дерматовенерология. Под ред. А.А. Кубановой. Клинические рекомендации. Российское общество дерматовенерологов. М., 2010. 428 с.
  13. Лучшев В.И., Жаров С.Н., Кузнецова И.В. Рожа: клиника, диагностика, лечение. Росс. мед. журн. 2012;3:42-4.
  14. Vinh D.C., Embil J.M. Rapidly progressive soft tissue infections. Lancet Infect. Dis. 2005; 5:501-13.
  15. Hartman-Adams H., Banvard C., Juckett G. Impetigo: diagnosis and treatment. Am. Fam. Physician. 2014;90(4):229-35.
  16. Silverberg N., Block S. Uncomplicated skin and skin structure infections in children: diagnosis and current treatment options in the United States. Clin. Pediatr. (Phila). 2008;4 7(3):211-19.
  17. Agache P., Amblard P., Moulin G., Barœre H., Texier L., Beylot C., Bergoend H. Roxithromycin in skin and soft tissue infections. J. Antimicrob.Chemother. 1987;20(Suppl. B):153-56.
  18. Young R.A., Gonzalez J.P., Sorkin E.M. Roxithromycin: a review of its antibacterail activity, pharmacokinetic properties and clinical efficacy. Drugs. 1989;37:8-41.
  19. Markham A., Faulds D. Roxithromycin. An update of its antimicrobial activity, pharmacokinetic properties and therapeutic use. Drugs. 1994;48(2):297-326.
  20. Ianaro A., Ialenti A., Maffia P., Sautebin L., Romboh L., Carnuccio R., Iuvone T., D'Acquisto F., Di Rosa M. Anti-inflammatory activity of macrolide antibiotics. Pharmacol. Exp. Ther. 2000;292(1):156-63.
  21. Zalewska-Kaszubska J., Gorska D. Anti-inflammatory capabilities of macrolides. Pharmacol. Res. 2001;44:451-54.
  22. Tsuda T., Ishikawa C., Konishi H., Hayashi Y., Nakagawa N., Matsuki M., Mizutani H., Yamanishi K. Effect of 14-membered-ring macrolides on production of interleukin-8 mediated by protease-activated receptor 2 in human keratinocytes. Antimicrob. Agents Chemother. 2008;52(4):1538-41.
  23. Karakawa M., Komine M., Tamaki K, Ohtsuki M. Roxithromycin downregulates production of CTACK/CCL27 and MIP-3a/CCL20 from epidermal keratinocytes. Arch. Dermatol. Res. 2010;302(10):763-67.
  24. Puri S.K., Lassman H.B. Roxithromycin: a pharmacokinetic review of a macrolide. J. Antimicrob. Chemother. 1987;20 (Suppl. B):89-100.
  25. Lassman H.B.,PuriS.K.,HoI.,Sabo R.,MezzinoM.J. Pharmacokinetics of roxithromycin (RU 965). J. Clin. Pharmacol. 1988;28:141-52.
  26. Nilsen O.G., Aamo T., Zahlsen K., Svarva P. Macrolide pharmacokinetics and dose scheduling of roxithromycin. Diagn. Microbiol. Infect.Dis. 1992;15(Suppl. 4):71-6.
  27. Дымов А.М., Локшин К.Л. Обзор результатов клинических исследований лекарственного препарата Эспарокси в лечении негонококкового уретрита у мужчин. Эффективная фармакотерапия. 2012;5: 10-3.
  28. Birkett D.J., Robson R.A, Grgurinovich N., Tonkin A. Single oral dose pharmacokinetics of erythromycin and roxithromycin and the effects of chronic dosing. Ther. Drug Monit. 1990;12:65-71.
  29. Campa M., Zolfino I., Senesi S., Bernardini N., Danesi R., Ducci M., Oleggini M., Di Stefano R., Mosca F., Lazzarini A. The penetration of roxithromycin into human skin. J. Antimicrob. Chemother. 1990;26:87-90.
  30. Walter K., Kurz H. Binding of drugs to human skin: influencing factors and the role of tissue lip ids. J. Pharm. Pharmacol. 1988;40(10):689-93.
  31. Nohara N., Akagi M., Kanzaki H. Comparative double blind test of roxithromycin and josamycin on purulent diseases. Chemotherapy Tokyo. 1989;37:1518-19.
  32. Bernard P., Plantin P., Roger H., Sassolas B., Villaret E., Legrain V., Roujeau J.C., Rezvani Y., Scheimberg A. Roxithromycin versus penicillin in the treatment of erysipelas in adults: a comparative study. Br. J. Dermatol. 1992;127:155-59.
  33. Marsac J.H. An international clinical trial on the efficacy and safety of roxithromycin in 40,000 patients with acute community-acquired respiratory tract infections. Diagn. Microbiol. Infect. Dis. 1992;15(Suppl. 4):81-4.
  34. Higuera-Ramirez F., Hidalgo H. Multicentre study of the efficacy and tolerability of roxithromycin in the treatment of respiratory tract infections. Drug Invest. 1991;3(Suppl. 3):38-46.
  35. Blanc F., D'Enfert J., Fiessinger S., et al. An evaluation of tolerance of roxithromycin in adults. J. Antimicrob. Chemother. 1987;20(Suppl. B):179-83.
  36. Delcourt A., Lambert M., Brenard R. Reversible liver injury possibly due to roxithromycin therapy. Acta Clin. Belg. 1990;45(3):206-7.
  37. Pedersen F.M., Bathum L., Fenger C. Acute hepatitis and roxithromycin. Lancet. 1993; 341:251-52.
  38. Pillans P., Maling T. Roxithromycin and hepatitis. Drug Invest. 1993;6:296-99.
  39. Roujeau J.-C., Bioulac-Sage P., Bourseau C., et al. Acute generalized exanthematous pustulosis. Arch. Dermatol. 1991;127:1333-38.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies